Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Bayer Prices Stivarga With Crowded Colon Cancer Market In Mind

This article was originally published in The Pink Sheet Daily

Executive Summary

Ahead of schedule, FDA approves Stivarga (regorafenib), partnered with Onyx, for late-stage mCRC patients with few options left. Bayer prices drug at under $10,000 a month, on par with competing treatments.


Related Content

Market Snapshot: Zaltrap Changes Cost-Benefit Expectations For New Colon Cancer Drugs
Bayer Oncology Keystone Nexavar Looks Good For Thyroid Indication
Bayer/Onyx Stick To Advanced Cancer Setting With Stivarga’s GIST Indication
Business News, In Brief
Top Changes At Bayer And Novartis As Vasella Goes, Reinhardt Returns
Questioning Stivarga’s Cost-Effectiveness In Colon Cancer
Kyprolis Launch Strength Shows Onyx Commercial Savvy
Market For Sanofi And Regeneron’s Zaltrap Could Be Limited
Can Erbitux Make Inroads In First-line Colon Cancer With Approved Companion Dx In Tow?
Phase III Trial Of Bayer/Onyx Regorafenib Stopped Early For Efficacy


Related Companies




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts